PFE Stock 12 Month Forecast $31.56 ▲(24.99% Upside) Based on19Wall Street analysts offering 12 month price targets forPfizerin the last3 months. The average price target is$31.56with a high forecast of$45.00and a low forecast of$25.00. The average price target represents a24.99%change from...
Targets 6-month : 31.36 1-year : 36.62 Resists First : 26.85 Second : 31.36 Pivot price 26.06 Supports First : 25.74 Second : 25.05 MAs MA(5) : 26.57 MA(20) : 25.96 MA(100) : 27.8 MA(250) : 27.88 MACD MACD : 0 Signal : -0.1 %K %D K(14,3) : 82.2 D(3) : ...
which affected our stock price performance. Despite however this challenging year, there were a few great things that happened in 2023 that may have gotten lost amid the mixed expectations. First, in 2023, Pfizer impacted the lives of more than 620 million ...
This new authorization represented approximately 10.1% of shares outstanding at the stock price at the time of the announcement.Sale of select assets of BioReference Health expected to close toward the end of the third quarter. OPKO entered into an agreement in March 2024 to sell BioReference ...
Pfizer Share Price Pfizer is listed on the New York Stock Exchange under the NYSE:PFE ticker, and is a component of the Dow Jones Industrial Average and the S&P 500. Since January 2020, prior to the coronavirus crisis, Pfizer shares have lost a little over 17%, primarily due to the loss...
Stock Price Performance Despite the FDA’s approval of mRNA-based vaccines, stocks of all vaccine-makers fell during trading on Thursday. Post the announcement, shares of Pfizer, BioNTech and Moderna were down 0.9%, 2.0% and 6.5%, respectively. These dips in stock prices of vaccine-makers wer...
To us, this means that Pfizer's "re-basing" could take too long to make the stock "investable" today, despite its temptingly low valuation and its significant cash flow generation. While the pending Lipitor patent expiration garners the most attention, the vast majority of Pfizer's key ...
Pfezier, the world’s biggest drugmaker, said it will use the proceeds of the sale to buy back additional stock and may use some of the funds to make other investments. In 2010, Capsugel recorded $750 million in revenue and manufactured more than 180 billion hard capsules. ...
the risk that the businesses will not be integrated successfully; negative effects of the consummation of the acquisition on the market price of Pfizer’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions relat...
Wrapping up with a quick look at the stock market 股市收盘情况 Chinese stocks rose on Monday with the benchmark Shanghai Composite gaining 0.58 percent, while the Shenzhen Component climbed 0.73 percent. Hong Kong stocks ended with more gains as quarantine-free border travel with the mainland wen...